A23V2250/708

Multivitamin extrudates
11278046 · 2022-03-22 · ·

This invention relates generally to multivitamin extrudates. Their production as well as their use.

Lutein microcapsule formulation and preparation method thereof

A lutein microcapsule formulation and preparation method thereof, the formulation comprising the following ingredients: lutein crystals, a water-soluble emulsifier, an oil-soluble antioxidant, a wall material, a filler, a water-soluble antioxidant, and purified water. The preparation method comprises: dissolving the lutein crystals and the oil-soluble antioxidant in the water-soluble emulsifier to obtain an oil phase; adding the wall material, the water-soluble antioxidant, and the filler to the purified water to obtain a water phase; adding the oil phase to the water phase, grinding to obtain a particle size of the liquid emulsion of less than 100 nm, and granulating.

Lutein microcapsule formulation and preparation method thereof

A lutein microcapsule formulation and preparation method thereof, the formulation comprising the following ingredients: lutein crystals, a water-soluble emulsifier, an oil-soluble antioxidant, a wall material, a filler, a water-soluble antioxidant, and purified water. The preparation method comprises: dissolving the lutein crystals and the oil-soluble antioxidant in the water-soluble emulsifier to obtain an oil phase; adding the wall material, the water-soluble antioxidant, and the filler to the purified water to obtain a water phase; adding the oil phase to the water phase, grinding to obtain a particle size of the liquid emulsion of less than 100 nm, and granulating.

GREEN TEA-CONTAINING BEVERAGE, METHOD FOR PREVENTING DISCOLORATION OF GREEN TEA-CONTAINING BEVERAGE, AND METHOD FOR MANUFACTURING GREEN TEA-CONTAINING BEVERAGE
20220071225 · 2022-03-10 · ·

Provided is a green tea-containing beverage including: (A) green tea; (B) at least one selected from the group consisting of phytic acid, tartaric acid, and gluconic acid; and (C) at least one selected from the group consisting of ascorbic acid, a salt of ascorbic acid, erythorbic acid, and a salt of erythorbic acid, wherein the green tea-containing beverage has a copper content of 0.3 mg/L or more. Preferably, the concentration of the constituent (B) is 0.05-2.5 g/L. Preferably, the concentration of the constituent (C) is 0.2-5 g/L. Preferably the green tea-containing beverage further includes alcohol. Also provided is a method for preventing discoloration of a green tea-containing beverage, the method including: incorporating the constituents (B) and (C) in the green tea-containing beverage; and further incorporating copper so as to give the copper content of 0.3 mg/L or more.

GREEN TEA-CONTAINING BEVERAGE, METHOD FOR PREVENTING DISCOLORATION OF GREEN TEA-CONTAINING BEVERAGE, AND METHOD FOR MANUFACTURING GREEN TEA-CONTAINING BEVERAGE
20220071225 · 2022-03-10 · ·

Provided is a green tea-containing beverage including: (A) green tea; (B) at least one selected from the group consisting of phytic acid, tartaric acid, and gluconic acid; and (C) at least one selected from the group consisting of ascorbic acid, a salt of ascorbic acid, erythorbic acid, and a salt of erythorbic acid, wherein the green tea-containing beverage has a copper content of 0.3 mg/L or more. Preferably, the concentration of the constituent (B) is 0.05-2.5 g/L. Preferably, the concentration of the constituent (C) is 0.2-5 g/L. Preferably the green tea-containing beverage further includes alcohol. Also provided is a method for preventing discoloration of a green tea-containing beverage, the method including: incorporating the constituents (B) and (C) in the green tea-containing beverage; and further incorporating copper so as to give the copper content of 0.3 mg/L or more.

Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye Disorders
20210315833 · 2021-10-14 ·

Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.

Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye Disorders
20210315833 · 2021-10-14 ·

Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.

FORMULATIONS OF PHOSPHOLIPID COMPRISING OMEGA FATTY ACIDS
20210307349 · 2021-10-07 · ·

Disclosed herein are stabilized powder and aqueous formulations comprising a phospholipid comprising omega fatty acid and a micelle-forming surfactant. In one embodiment, the formulation further comprises a water soluble reducing agent, and/or a metal chelator, and/or a metal bisulfite reducing agent, or combinations thereof, wherein the formulation remains substantially clear and stable when stored at or below room temperature for a period of at least 6 months or at least 12 months; and methods for preparing these formulations.

FORMULATIONS OF PHOSPHOLIPID COMPRISING OMEGA FATTY ACIDS
20210307349 · 2021-10-07 · ·

Disclosed herein are stabilized powder and aqueous formulations comprising a phospholipid comprising omega fatty acid and a micelle-forming surfactant. In one embodiment, the formulation further comprises a water soluble reducing agent, and/or a metal chelator, and/or a metal bisulfite reducing agent, or combinations thereof, wherein the formulation remains substantially clear and stable when stored at or below room temperature for a period of at least 6 months or at least 12 months; and methods for preparing these formulations.

Cannabinoid emulsion product and process for making the same
11134710 · 2021-10-05 · ·

A dry consumable preparation and related methods are disclosed. The preparation has a bulking agent, and a cannabinoid and/or a cannabinoid extract containing one or more cannabinoids plated onto the bulking agent. The preparation also has an effervescence agent. The effervescence agent has sodium bicarbonate, potassium bicarbonate, and at least one acid, the at least one acid having at least one of citric acid, tartaric acid, or malic acid. The effervescence agent further has a ratio of sodium bicarbonate to potassium bicarbonate to the acid(s) that creates a chemical pH buffering system at a targeted pH range when the dry consumable preparation is added to a targeted amount of water.